Subject(s)
Analgesics, Opioid , Methadone , Humans , Methadone/administration & dosage , Child , Intraoperative Care/methods , Pediatrics/methodsSubject(s)
Anaphylaxis , Sugammadex , gamma-Cyclodextrins , Humans , Sugammadex/adverse effects , Anaphylaxis/chemically induced , Anaphylaxis/diagnosis , gamma-Cyclodextrins/adverse effects , Neuromuscular Nondepolarizing Agents/adverse effects , Female , Rocuronium/adverse effects , Rocuronium/administration & dosage , Male , Drug Hypersensitivity/diagnosis , Drug Hypersensitivity/etiology , Middle Aged , Androstanols/adverse effectsABSTRACT
Residual neuromuscular block (RNMB) remains a significant safety concern for patients throughout the perioperative period and is still widely under-recognized by perioperative healthcare professionals. Current literature suggests an association between RNMB and an increased risk of postoperative pulmonary complications, a prolonged length of stay in the post anesthesia care unit (PACU), and decreased patient satisfaction. The 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade provide guidance for the use of quantitative neuromuscular monitoring coupled with neuromuscular reversal to recognize and reduce the incidence of RNMB. Using sugammadex for the reversal of neuromuscular block as well as quantitative neuromuscular monitoring to quantify the degree of neuromuscular block may significantly reduce the risk of RNMB among patients undergoing general anesthesia. Studies are forthcoming to investigate how using neuromuscular blocking agent reversal with quantitative monitoring of the neuromuscular block may further improve perioperative patient safety.
